Clinical characteristics of prostate cancer in an analysis of linkage to four putative susceptibility loci
- PMID: 11555587
Clinical characteristics of prostate cancer in an analysis of linkage to four putative susceptibility loci
Abstract
Purpose: Hereditary prostate cancer is an etiologically heterogeneous disease with six susceptibility loci mapped to date. We aimed to describe a collection of high-risk prostate cancer families and assess linkage to multiple markers at four loci: HPC1 (1q24-25), PCaP (1q42.2-43), HPCX (Xq27-28), and CAPB (1p36).
Experimental design: Medical record data on 505 affected men in 149 multiply-affected prostate cancer families were reviewed, and correlations of clinical traits within each family were calculated. Logarithm of odds (LOD) score and nonparametric (NPL) linkage analyses were performed; white families were stratified by age of diagnosis, grade and stage of disease, and evidence of linkage to the other loci to increase genetic homogeneity.
Results: Age at diagnosis was the most correlated clinical trait within families. A maximum NPL score of 2.61 (P = 0.007) appeared to confirm HPC1 linkage for families that had a prevalence of high-grade or advanced-stage prostate cancer and which were not likely to be linked to PCaP, HPCX, or CAPB. Because the NPL scores improved when families more likely to be linked to the other loci were excluded, HPC1 may act independently of the other loci. The relationship of HPC1 and aggressive disease was strongest in families with median age at diagnosis > or =65 years (NPL, 3.48; P = 0.0008).
Conclusions: The current results suggest that HPC1 linkage may be most common among families with more severe prostate cancer. Stratification by clinical characteristics may be a useful tool in prostate cancer linkage analyses and may increase our understanding of hereditary prostate cancer.
Similar articles
-
PCAP is the major known prostate cancer predisposing locus in families from south and west Europe.Eur J Hum Genet. 2001 Feb;9(2):135-42. doi: 10.1038/sj.ejhg.5200592. Eur J Hum Genet. 2001. PMID: 11313747
-
A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with late-onset disease.Clin Cancer Res. 2000 Dec;6(12):4810-5. Clin Cancer Res. 2000. PMID: 11156239
-
Genome linkage screen for prostate cancer susceptibility loci: results from the Mayo Clinic Familial Prostate Cancer Study.Prostate. 2003 Dec 1;57(4):335-46. doi: 10.1002/pros.10308. Prostate. 2003. PMID: 14601030
-
The complex genetic epidemiology of prostate cancer.Hum Mol Genet. 2004 Apr 1;13 Spec No 1:R103-21. doi: 10.1093/hmg/ddh072. Epub 2004 Jan 28. Hum Mol Genet. 2004. PMID: 14749351 Review.
-
Involvement of the RNAse L gene in prostate cancer.Bull Soc Sci Med Grand Duche Luxemb. 2006;(1):21-8. Bull Soc Sci Med Grand Duche Luxemb. 2006. PMID: 16869093 Review.
Cited by
-
Pathological aggressiveness of prostatic carcinomas related to RNASEL R462Q allelic variants.J Urol. 2008 Apr;179(4):1344-8. doi: 10.1016/j.juro.2007.11.078. Epub 2008 Mar 4. J Urol. 2008. PMID: 18289577 Free PMC article. Clinical Trial.
-
A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region.Hum Genet. 2005 Aug;117(4):307-16. doi: 10.1007/s00439-005-1306-z. Epub 2005 May 20. Hum Genet. 2005. PMID: 15906096
-
The precise role of ethnicity and family history on aggressive prostate cancer: a review analysis.Arch Esp Urol. 2011 Oct;64(8):711-9. Arch Esp Urol. 2011. PMID: 22052754 Free PMC article. Review.
-
2-5A-Mediated decay (2-5AMD): from antiviral defense to control of host RNA.Crit Rev Biochem Mol Biol. 2022 Oct-Dec;57(5-6):477-491. doi: 10.1080/10409238.2023.2181308. Epub 2023 Mar 20. Crit Rev Biochem Mol Biol. 2022. PMID: 36939319 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical